Table 1.
Patient and tumor characteristics of 381 patients, divided into the CROSS (n = 208) and post-CROSS (n = 173) cohorts for patients with oesophageal or junctional cancer who underwent neoadjuvant chemoradiotherapy according to CROSS followed by surgery
| CROSS | Post-CROSS | |||
|---|---|---|---|---|
| N (%) | N (%) | p value | ||
| Total | 208 | 173 | ||
| Age, years | Mean [SD] | 60 [0.8] | 62 [0.7] | 0.004 |
| <60 | 107 (51) | 62 (36) | 0.001 | |
| 60–65 | 37(18) | 36 (21) | ||
| 66–69 | 35 (17) | 33 (19) | ||
| 70–75 | 27 (13) | 28 (16) | ||
| > 75 | 2 (1) | 14 (8) | ||
| Sex | Male | 163 (78) | 137 (79) | 0.8 |
| Female | 45 (22) | 36 (21) | ||
| Comorbidity | No | 162 (78) | 113 (65) | 0.002 |
| One or more | 46 (22) | 60 (35) | ||
| Charlson index | 0 | 162 (78) | 110 (64) | 0.007 |
| 1 | 40 (19) | 48 (28) | ||
| 2 | 6 (3) | 14 (8) | ||
| 3 | ||||
| Karnofsky performance status | 60 | 1 (0) | 0 (0) | 0.000 |
| 70 | 2 (1) | 0 (0) | ||
| 80 | 9 (4) | 16 (9) | ||
| 90 | 90 (44) | 126 (73) | ||
| 100 | 73 (35) | 8 (5) | ||
| Missing | 33 (16) | 23 (13) | ||
| Tumor length, cm | Mean [SD] | 4.5 [0.15] | 5.1 [0.19] | 0.008 |
| ≤ 8 | 183 (86) | 154 (91) | ||
| > 8 | 7 (4) | 16 (9) | 0.02 | |
| Missing | 18 (9) | 3 (2) | ||
| Clinical T stage | T1 | 1 (0) | 9 (5) | 0.04 |
| T2 | 30 (14) | 37 (21) | ||
| T3 | 176 (85) | 115 (66) | ||
| T4 | 0 (0) | 8 (5) | ||
| Missing | 1 (0) | 4 (2) | ||
| Clinical N stage | N0 | 78 (37) | 53 (31) | 0.000 |
| N1 | 114 (55) | 54 (31) | ||
| N2 | 13 (6) | 55 (31) | ||
| N3 | 2 (1) | 8 (4) | ||
| Missing | 1 (0) | 3 (2) | ||
| Histology | Adenocarcinoma | 160 (77) | 133 (76) | 0.5 |
| Squamous cell carcinoma | 48 (23) | 40 (23) |
CROSS ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study, SD standard deviation